The State of Reproductive Organs of Young and Aged Male Rats at the Prolong Administration of Letrozole and after its Withdrawal
DOI: 207 Downloads 5990 Views
Author(s)
Abstract
Aim.Study of the reproductive organs at long-term administration of letrozole, the steroid aromatase inhibitor, followed by its withdrawal in young male rats and ones with age-related involution of reproductive organs.Material and methods. The experiments were carried out on Wistar rats with an initial age of 5 months and 15 months, which have been gavaged by letrozole every other day at a dose of 1 mg/kg b. w for 3 months and then 2 months after its discontinuation. The blood plasma testosterone and estradiol levels were measured by immunoassays. The spermatozoa concentrations in epididymal washes were determined. The testicles and accessory sexual glands were weighed, and morphology of gonads and ventral prostate have been studied. The results of the study were compared with those of control animals of corresponding age. Results.As the result of letrozole treatment, the ratio of testosterone and estradiol levels in blood plasma of aged rats increased. The spermatozoa content in epididymis rose up by 28% at average. The histological study revealed functional activation of Leydig cells, a significant retardation of involutive changes of their number and morphology. Some Leydig cells demonstrated the signs of functional exhaustion. Letrozole exerted an increase of relative weights of the coagulation gland by an average of 40%, seminal vesicles by 31%, and ventral prostate by 33% compared with those of control animals. Two months after letrozolewithdrawal, there were no any signs of difference between letrozole-treated and control animals. In young rats, the effects of letrozole were almost not detectable. Conclusions.Letrozole administration to male rats with age-related involution of the reproductive system increases testosterone/estradiol ratio in blood plasma, the spermatozoa content in epididymises and the weights of androgen-dependent accessory sexual glands. This is accompanied by slowing down of age-related changes of the gonad and prostate gland morphology. Letrozole-induced reproductive effects are reversible.
Keywords
letrozole, reproductive organs, male, rats.
Cite this paper
Alexander G. Reznikov, Olga V. Sachynska, Lyubov I. Polyakova, Oksana A. Faliush, Alexander V. Yanishevskiy,
The State of Reproductive Organs of Young and Aged Male Rats at the Prolong Administration of Letrozole and after its Withdrawal
, SCIREA Journal of Medicine.
Volume 4, Issue 5, October 2020 | PP. 94-110.
References
[ 1 ] | Rastrelli, G., Maggi, M., Corona, G. (2018). Pharmacological management of late-onset hypogonadism. Expert Rev Clin Pharmacol., 11(4), 439–458. doi: 10.1080/17512433.2018.1445969. |
[ 2 ] | Luchytskyi, Ye. V., Luchytskyi, V. Ye. (2012). [Modern concept of age androgendefiсiensy in males]. Endokrynologia, 4, 56–60. [in Ukraine]. |
[ 3 ] | Reznikov, A. G. (2014). [The point of view of pathophysiologist-endocrinologist on the problem of age-related androgen deficiency in men (LOH-syndrome]. Mizhnarodnyi endocrinologichnyi zhurnal [International Journal of Endokrinology], 6(62), 11–18. [in Ukraine]. |
[ 4 ] | Ahmed, K., Hatzimouratidis, K., Muneer, A. (2017). Male sexual dysfunction and hypogonadism Guidelines for the aging male. EurUrol Focus, 3(4-5), 514–516. doi: 10.1016/j.euf.2017.12.004. |
[ 5 ] | Decaroli, M. C., &Rochira, V. (2017). Aging and sex hormones in males. Virulence, 8(5), 545–570.doi: [10.1080/21505594.2016.1259053]. |
[ 6 ] | Blaya, R., Blaya, P., Rhoden, L., Rhoden, E. L. (2017). Low testosterone levels and metabolic syndrome in aging male. Curr Pharm Des, 23(30), 4470–4474. doi: 10.2174/1381612823666170503150955. |
[ 7 ] | Pye, S. R., Huhtaniemi, I. T., Finn,J. D., Lee, D. M., O'Neill, T. W., Tajar, A., et al. (2014). Late-onset hypogonadism and mortality in aging men. J. Clin. Endocrinol. Metab., 99(4), 1357–1366.doi: 10.1210/jc.2013-2052. |
[ 8 ] | Rhoden, E. L., Morgentaler, A. (2004). Risks of testosterone-replacement therapy and recommendations for monitoring. New England J. Med., 350(5), 482–492. doi: 10.1056/NEJMra022251. |
[ 9 ] | Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., Montori, V. M. (2006). Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab., 91(6), 1995–2010. https://doi.org/10.1210/jc.2005-2847. |
[ 10 ] | Solov´ev, A. I., Reznikov, A. G., Tarasenko, L. V., Margitich, V. M. (2006). [The first successful biowaiver application in Ukraine for the expert evaluation of a medicinal product (Letromara)]. Zhurnal AMN Ukrainy, 12(4), 781–793. [in Ukraine]. |
[ 11 ] | Tarasenko, L. V., Reznikov, O. G. (2007). [Pathogenetic role of ovarian steroid aromatase in disorders of sexual cycle]. Fiziolohichnyi Zhurnal, 53(1), 11–15. [in Ukraine]. |
[ 12 ] | Bhatnagar, A. S., Muller, P., Schenkel, L., Trunet, P. F., Beh, I.,Schieweck, K. (1992). Inhibition of estrogen biosynthesis and its consequences on gonadotrophin secretion in the male. J. Steroid Biochem Mol. Biol., 41(3–8), 437–443.https://doi.org/10.1016/0960-0760(92)90369-T. |
[ 13 ] | De Boer, H., Verschoor, L., Ruinemans-Koerts, J., Jansen, M. (2005). Letrozole normalizes serum testosterone in severely obese men with hypogonadotropic hypogonadism. Diabetes, Obesity and Metabolism, 7(3), 211–215. doi: 10.1111/j.1463-1326.2004.00397.x |
[ 14 ] | Loves, S., Ruinemans-Koerts, J., De Boer, H. (2008). Letrozole once a week normalizes serum testosterone in obesity-related male hypogonadism. European J. Endocrinol., 158(5), 741–747. doi: 10.1530/EJE-07-0663. |
[ 15 ] | De Ronde, W., De Jong, F. H. (2011). Aromatase inhibitors in men: effects and therapeutic options. Reprod. Biol. Endocrinol.., 9, 93. doi: 10.1186/1477-7827-9-93. |
[ 16 ] | Zhao, D., Pan, L., Zhang, F., Pan, F., Ma, J., Zhang, X., Liu, Y. (2014). Successful use of aromatase inhibitor letrozole in NOA with an elevated FSH level: a case report. Andrologia, 46(4), 456–457. doi: 10.1111/and.12122. |
[ 17 ] | Ribeiro, M. A., Gameiro, L. F., Scarano, W. R., Briton-Jones, C., Kapoor, A., Rosa, M. B., El Dib, R. (2016). Aromatase inhibitors in the treatment of oligozoospermic or azoospermic men: a systematic review of randomized controlled trials. JBRA Assist. Reprod., 20(2), 82–88. doi: 10.5935/1518-0557.20160019. |
[ 18 ] | Bibancos, M., Cavagnoli, M., Bonetti, T. C., Semaco, E., Motta, E. L.,Serafini, P. C. (2015). Letrozole Therapy for obstructive azoospermic men before in vitro fertilization (IVF) treatment with percutaneous epididymal sperm aspiration. JBRA Assist. Reprod., 19(4), 230–234. doi: 10.5935/1518-0557.20150045. |
[ 19 ] | Gregoriou, O., Bakas, P., Grigoriadis, C., Creatsa, M., Hassiakos, D., Creatsas, G. (2012). Changes in hormonal profile and seminal parameters with use of aromatase inhibitors in management of infertile men with low testosterone to estradiol ratios. Fertil. Steril, 98(1), 48–51. doi: 10.1016/j.fertnstert.2012.04.005. |
[ 20 ] | Leder, B. Z., Rohrer, J. L., Rubin, S. D., Gallo, J., Longcope, C. (2004). Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels. J. Clin. Endocrinol. Metab, 89(3), 1174–1180.doi: 10.1210/jc.2003-031467. |
[ 21 ] | Burnett-Bowie, S. A., Roupenian, K. C., Dere, M. E., Lee, H., Leder, B. Z. (2009). Effects of aromatase inhibition in hypogonadal older men: a randomized, double-blind, placebo-controlled trial. Clin. Endocrinol., 70(1), 116–123. doi: 10.1111/j.1365-2265.2008.03327.x. |
[ 22 ] | Schlegel, P. N. (2012). Aromatase inhibitors for male infertility. Fertil. Steril, 98(6), 13559–13562.doi: 10.1016/j.fertnstert.2012.10.023. |
[ 23 ] | Tan, R. B., Guay, A. T., Hellstrom, W. J. (2014). Clinical Use of Aromatase inhibitors in adult males. Sex Med. Rev, 2(2), 79–90. doi: 10.1002/smrj.23. |
[ 24 ] | Turner, K. J., Morley, M., Atanassova, N., Swanston, I. D., Sharpe, R. M. (2000). Effect of chronic administration of an aromatase inhibitor to adult male rats on pituitary and testicular function and fertility. J. Endocrinol., 162(2), 225–238. |
[ 25 ] | Pouliot, L., Schneider, M., DeCristofaro, M., Samadfam, R., Smith, S. Y., Beckman, D. A. (2013). Assessment of a nonsteroidal aromatase inhibitor, letrozole, in juvenile rats. Birth Defects Res. B. Dev.Reprod.Toxicol., 98(5), 374–390. doi: 10.1002/bdrb.21080. |
[ 26 ] | Selim, M. E., Aleisa, N. A., Daghestani, M. H. (2013). Evaluation of the possible protective role of quercetin on letrozole-induced testicular injury in male albino rats. Ultrastruct. Pathol, 37(3), 204–217.doi: 10.3109/01913123.2013.772269. |
[ 27 ] | Reznikov, O. G., Chaikovska, L. V., Polyakova, L. I., Sachynska, O. V., Yanishevsky, O. V. (2015). [Age-related peculiarities of the response of male rat reproductive system to letrozole]. .Endokrynologia, 20(1), 425–430. [in Ukraine]. |
[ 28 ] | Zapadnyuk, I. P., Zapadnyuk, V. I., Zakhariya, E. A. (1974) [Laboratory animals].Kyiv. [in Ukraine]. |
[ 29 ] | Gelashvily, O. A. (2008). [Variant of periodization of biologically similar stages of human and rat’s ontogenesis]. Saratovskij Nauchno-meditsinski Zzhurnal, 4(22), 125–126. [in Russian]. |
[ 30 ] | Vanderschueren, D., Boonen, S., Ederveen, A. G., de Coster, R., Van Herck, E., Moermans, K., et al. (2000). Skeletal effects of estrogen deficiency as induced by an aromatase inhibitor in an aged male rat model. Bone, 27(5), 611–617. |